Immune-Onc - Model IO-106 - (Anti-LAIR1) Mechanisms of Action Program

Researchers have shown that expression of the inhibitory receptor Leukocyte-Associated Immunoglobulin-Like Receptor 1 (LAIR1) correlates with worse survival in several cancers. Studies suggest that binding of LAIR1 to its ligand collagen leads to T-cell suppression and exhaustion, as well as dendritic cell deactivation in the tumor microenvironment.

IO-106 is a first-in-class monoclonal antibody that antagonizes LAIR1. It has broad potential in collagen-rich solid tumors and could be a candidate for combination therapy with anti-PD-(L)1 or other immunotherapies. Preclinical research shows that IO-106 can reverse collagen-mediated immune suppression and mobilize anti-tumor immunity of multiple cell types including lymphocytes and myeloid cells.